妊娠早期SARS-CoV-2感染与早期流产风险:一项英国前瞻性队列研究,纳入疫情期间受孕的3041例妊娠
这项英国全国前瞻性队列研究通过社交媒体招募3545例妊娠早期孕妇,最终3041例有主要结局数据。自我报告妊娠早期确诊SARS-CoV-2感染的孕妇早期流产率为14%,高于不确定组5%和推定未感染组8%(P=0.02);调整混杂因素后相对风险为1.7(95%CI 1.0-3.0,P=0.06)。
要点
- 自我报告妊娠早期确诊SARS-CoV-2感染组早期流产率为14%(11/77)。
- 不确定组早期流产率为5%(15/295),推定未感染组为8%(212/2669)。
- 调整后相对风险1.7(95%CI 1.0-3.0,P=0.06),作者认为可能增加风险。
核心结论
- 妊娠早期自我报告确诊SARS-CoV-2感染的孕妇早期流产风险似乎更高,但调整后相对风险95%CI跨1,未达统计学显著。
研究设计与样本
- 这是一项英国全国前瞻性队列研究,通过社交媒体在2020年5月21日至12月31日招募社区孕妇。
- 共招募3545例在SARS-CoV-2疫情期间受孕且招募时妊娠<13周的孕妇,其中3041例(86%)有主要结局数据。
主要发现
- 总体自我报告流产率为7.8%(238/3041,95%CI 7-9),流产时中位孕周为9周(四分位距8-11)。
- 推定感染组77/3041(2.5%,95%CI 2-3),不确定组295/3041(9.7%,95%CI 9-11),推定未感染组2669/3041(87.8%,95%CI 87-89)。
- 早期流产率推定感染组14%(11/77,95%CI 6-22)vs 不确定组5%(15/295,95%CI 3-8)vs 推定未感染组8%(212/2669,95%CI 7-9),P=0.02。
- 调整年龄、BMI、种族、吸烟状态、注册时孕周和既往流产次数后,推定感染组早期流产相对风险为1.7(95%CI 1.0-3.0,P=0.06)。
临床怎么用
- 作者认为妊娠早期感染SARS-CoV-2的孕妇流产风险可能增加,但研究人群总体流产率为8%,这一结果令人安心。
- 作者指出若SARS-CoV-2对流产风险有影响,可能仅限于症状严重到需要诊断检测者。
- 作者建议孕妇在整個妊娠期继续采取社交距离措施和良好卫生习惯以限制感染风险。
- 作者认为需要进一步研究评估妊娠早期SARS-CoV-2感染与流产风险的因果关联。
局限性
- 研究依赖自我报告的早期妊娠丢失和SARS-CoV-2感染数据,无法核实有效性。
- 推定未感染组和不确定组中部分孕妇可能存在无症状感染。
- 研究中推定感染组人数较少,因此研究把握度相对不足。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Does maternal infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the first trimester affect the risk of miscarriage before 13 week's gestation? SUMMARY ANSWER: Pregnant women with self-reported diagnosis of SARS-CoV-2 in the first trimester had a higher risk of early miscarriage. WHAT IS KNOWN ALREADY: Viral infections during pregnancy have a broad spectrum of placental and neonatal pathology. Data on the effects of the SARS-CoV-2 infection in pregnancy are still emerging. Two systematic reviews and meta-analyses reported an increased risk of preterm birth, caesarean delivery, maternal morbidity and stillbirth. Data on the impact of first trimester infection on early pregnancy outcomes are scarce. This is the first study, to our knowledge, to investigate the rates of early pregnancy loss during the SARS-CoV-2 outbreak among women with self-reported infection. STUDY DESIGN, SIZE, DURATION: This was a nationwide prospective cohort study of pregnant women in the community recruited using social media between 21 May and 31 December 2020. We recruited 3545 women who conceived during the SARS-CoV-2 pandemic who were <13 week's gestation at the time of recruitment. PARTICIPANTS/MATERIALS, SETTING, METHODS: The COVID-19 Contraception and Pregnancy Study (CAP-COVID) was an on-line survey study collecting longitudinal data from pregnant women in the UK aged 18 years or older. Women who were pregnant during the pandemic were asked to complete on-line surveys at the end of each trimester. We collected data on current and past pregnancy complications, their medical history and whether they or anyone in their household had symptoms or been diagnosed with SARS-CoV-2 infection during each trimester of their pregnancy. RT-PCR-based SARS-CoV-2 RNA detection from respiratory samples (e.g. nasopharynx) is the standard practice for diagnosis of SARS-CoV-2 in the UK. We compared rate of self-reported miscarriage in three groups: 'presumed infected', i.e. those who reported a diagnosis with SARS-CoV-2 infection in the first trimester; 'uncertain', i.e. those who did not report a diagnosis but had symptoms/household contacts with symptoms/diagnosis; and 'presumed uninfected', i.e. those who did not report any symptoms/diagnosis and had no household contacts with symptoms/diagnosis of SARS-CoV-2. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 3545 women registered for the CAP-COVID study at <13 weeks gestation and were eligible for this analysis. Data for the primary outcome were available from 3041 women (86%). In the overall sample, the rate of self-reported miscarriage was 7.8% (238/3041 [95% CI, 7-9]). The median gestational age (GA) at miscarriage was 9 weeks (interquartile range 8-11). Seventy-seven women were in the 'presumed infected' group (77/3041, 2.5% [95% CI 2-3]), 295/3041 were in the uncertain group (9.7% [95% CI 9-11]) and the rest in the 'presumed uninfected' (87.8%, 2669/3041 [95% CI 87-89]). The rate of early miscarriage was 14% in the 'presumed infected' group, 5% in the 'uncertain' and 8% in the 'presumed uninfected' (11/77 [95% CI 6-22] versus 15/295 [95% CI 3-8] versus 212/2669 [95% CI 7-9], P = 0.02). After adjusting for age, BMI, ethnicity, smoking status, GA at registration and the number of previous miscarriages, the risk of early miscarriage appears to be higher in the 'presumed infected' group (relative rate 1.7, 95% CI 1.0-3.0, P = 0.06). LIMITATIONS, REASONS FOR CAUTION: We relied on self-reported data on early pregnancy loss and SARS-CoV-2 infection without any means of checking validity. Some women in the 'presumed uninfected' and 'uncertain' groups may have had asymptomatic infections. The number of 'presumed infected' in our study was low and therefore the study was relatively underpowered. WIDER IMPLICATIONS OF THE FINDINGS: This was a national study from the UK, where infection rates were one of the highest in the world. Based on the evidence presented here, women who are infected with SARS-CoV-2 in their first trimester may be at an increased risk of a miscarriage. However, the overall rate of miscarriage in our study population was 8%. This is reassuring and suggests that if there is an effect of SARS-CoV-2 on the risk of miscarriage, this may be limited to those with symptoms substantial enough to lead to a diagnostic test. Further studies are warranted to evaluate a causal association between SARS-CoV-2 infection in early pregnancy and miscarriage risk. Although we did not see an overall increase in the risk of miscarriage, the observed comparative increase in the presumed infected group reinforces the message that pregnant women should continue to exercise social distancing measures and good hygiene throughout their pregnancy to limit their risk of infection. STUDY FUNDING/COMPETING INTEREST(S): This study was supported by a grant from the Elizabeth Garrett Anderson Hospital Charity (G13-559194). The funders of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. J.A.H. is supported by an NIHR Advanced Fellowship. A.L.D. is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre. All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: support to J.A.H. and A.L.D. as above; no financial relationships with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships or activities that could appear to have influenced the submitted work. TRIAL REGISTRATION NUMBER: N/A.
引用
- Balachandren N, Davies MC, Hall JA, et al. SARS-CoV-2 infection in the first trimester and the risk of early miscarriage: a UK population-based prospective cohort study of 3041 pregnancies conceived during the pandemic. Hum Reprod. 2022. PMID: 35389480. doi:10.1093/humrep/deac062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。